127 related articles for article (PubMed ID: 15601804)
1. Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects.
van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2005 Jan; 45(1):42-7. PubMed ID: 15601804
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
[TBL] [Abstract][Full Text] [Related]
3. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.
Bruderer S; Marjason J; Sidharta PN; Dingemanse J
Pharmacology; 2013; 91(5-6):331-8. PubMed ID: 23817130
[TBL] [Abstract][Full Text] [Related]
5. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.
Gutierrez MM; Nicolas LB; Donazzolo Y; Dingemanse J
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):529-36. PubMed ID: 23611572
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; Eggers H; Meyer J; van Marle S; Viischer HW; Jonkman JH
J Clin Pharmacol; 1999 Jul; 39(7):703-14. PubMed ID: 10392325
[TBL] [Abstract][Full Text] [Related]
7. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension.
Sasayama S; Kunieda T; Tomoike H; Matsuzaki M; Shirato K; Kuriyama T; Izumi T; Origasa H; Giersbergen PL; Dingemanse J; Tanaka S
Circ J; 2005 Feb; 69(2):131-7. PubMed ID: 15671601
[TBL] [Abstract][Full Text] [Related]
8. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.
Zhao Q; Brett M; Van Osselaer N; Huang F; Raoult A; Van Peer A; Verhaeghe T; Hust R
J Clin Pharmacol; 2002 Sep; 42(9):1002-10. PubMed ID: 12211216
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
[TBL] [Abstract][Full Text] [Related]
10. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Int J Clin Pharmacol Ther; 2002 Jul; 40(7):310-6. PubMed ID: 12139208
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
Barst RJ; Ivy D; Dingemanse J; Widlitz A; Schmitt K; Doran A; Bingaman D; Nguyen N; Gaitonde M; van Giersbergen PL
Clin Pharmacol Ther; 2003 Apr; 73(4):372-82. PubMed ID: 12709727
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.
Ermer J; Martin P; Corcoran M; Matsuo Y
Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers.
Sobue S; Tan K; Shaw L; Layton G; Hust R
Eur J Clin Pharmacol; 2004 Jun; 60(4):247-53. PubMed ID: 15103438
[TBL] [Abstract][Full Text] [Related]
16. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; Bodin F; Weidekamm E; Kutz K; van Giersbergen P
J Clin Pharmacol; 2002 Mar; 42(3):283-9. PubMed ID: 11865964
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.
Thomsen MS; Chassard D; Evène E; Nielsen KK; Jørgensen M
J Clin Pharmacol; 2003 Jan; 43(1):23-8. PubMed ID: 12520624
[TBL] [Abstract][Full Text] [Related]
19. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.
Weber C; Banken L; Birnboeck H; Schulz R
J Clin Pharmacol; 1999 Aug; 39(8):847-54. PubMed ID: 10434238
[TBL] [Abstract][Full Text] [Related]
20. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
